|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
 |
|
|
Imaging Bone (Flare) Responses in Advanced Prostate Cancer Presentation
|
|
Anwar Padhani MB, BS, FRCP, FRCR
|
| Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease.
|
|
|
|
|
|
|
|
|
|
 |
|
|
The Future of Advanced Prostate Cancer Imaging
|
|
Stefano Fanti, MD
|
| Stefano Fanti presents his point of view on the future of prostate cancer imaging. He shares his thoughts on the use of conventional imaging such as CT and bone scan and why they should be regarded as obsolete, and why novel imaging such as PET PSMA and MRI should be incorporated into practice immediately.
|
|
|
|
|
|
|
|
|
|
 |
|
|
Imaging Modalities to Treat Node-Positive Disease
|
Declan Murphy, MB, BCh, BaO, FRACS, FRCS Urol
Declan Murphy and Alicia Morgans share a conversation on men who have node positive but nonmetastatic prostate cancer and how we think about approaching treatment and integrating new imaging modalities into that entire therapeutic paradigm.
|
|
|
|
|
|
|
|
|
 |
|
|
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial
|
Oliver Sartor, MD
Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE
|
|
|
|
|
WE NEED YOUR VOICE - PARTICIPATE IN THIS STUDY
|
|
|
|
|
| Overview of the Treatment Landscape in Castration-Resistant Prostate Cancer
|
| Tanya Dorff, MD
|
| Tanya Dorff gave an overview highlighting the major changes and evolving areas in advanced prostate cancer management. Her talk focused on non-metastatic castrate-resistant prostate cancer (m0CRPC), oligometastatic prostate cancer, and metastatic CRPC (mCRPC).
|
|
|
|
|
|
| Reintroducing Therapeutics: Nuclear Medicine Physician Leading Patient Care Team
|
| Daniel Alexander Pryma, MD
|
| Daniel Pryma gave the first presentation of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Las-Vegas 2019. In his talk, he gave an overview of the nuclear medicine physician leading patient care team.
|
|
|
|
|
|
| Regulatory and Radiation Safety Requirements for Radiopharmaceutical Therapy
|
| Michael Sheetz, MS, CHP, DABMP
|
| Michael Sheetz presented on the regulatory and radiation safety requirements for radiopharmaceutical therapy. He began with some basic facts on the radiation regulatory oversight.
|
|
|
|
|
|
|
|
|
|
|
| Establishing Your Practice in Systemic Radiation Therapy in Theranostics Practice / The Role of Technologists in Theranostics Practice
|
| Alexander McEwan, MD
|
| Dr. Alexander (Sandy) McEwan gave an overview of establishing a practice in systemic radiation therapy. This important field of medicine entails the systemic administration of a targeted radionuclide utilizing short-range beta particles, alpha particles or electron emissions to achieve a clinically important outcome for a patient with primary or metastatic cancer.
|
|
|
|
|
|
| Current Status of 177 Lu-PSMA Targeted Therapies and Where Will We Be In the Near Future
|
| Phillip Kuo, MD, PhD
|
| In his talk at SNMMI 2019, Phillip Kuo described the current status of late-stage clinical trials, and the future landscape of 177-Lutetium-PSMA targeted therapies.
|
|
|
|
|
|
|
|
